Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (DE:1T3)
MUNICH:1T3
RESEARCH TOOLSreports
Syndax Pharmaceuticals (1T3) Stock Price & Analysis
1 Followers
1T3 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.40 - €22.00
Previous Close€19.4
Volume0.00
Average Volume (3M)N/A
Market Cap
€1.74B
Enterprise Value€1.21B
Total Cash (Recent Filing)$570.70M
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)N/A
Beta0.48
Next Earnings
May 08, 2024EPS Estimate
-€0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.29
Forecast
1Y Price Target
€31.37Price Target Upside61.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Syndax Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesPositive data from the AUGMENT-101 trial and a high response rate in pediatric patients underscore the potential of revumenib for treating acute leukemia.
Commercial Strategy And Revenue ProjectionsAnalyst projects significant revenue growth for revumenib, bolstered by a strong partnership with Incyte and a favorable safety profile.
Regulatory MilestonesSyndax received FDA priority review for its New Drug Application for revumenib, aiming to improve treatment for acute leukemia patients.
Bears Say
Drug Development ConcernsGrowing concerns about the company's ability to add new therapies due to adverse events could impact future prospects and market confidence.
Earnings RevisionAnalyst decreases FY24 EPS estimate significantly, reflecting expectations for greater losses.
Revenue ForecastAnalyst revises FY24 revenue estimate downward by a substantial margin, suggesting potential challenges ahead for the company's financial performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.66% Other Institutional Investors
99.34% Public Companies and
Individual Investors
1T3 FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was €10.40 and its highest was €22.00 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2024 which is in 6 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Feb 27, 2024. The company reported -€0.933 earnings per share for the quarter, missing the consensus estimate of -€0.903 by -€0.03.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -€0.91.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Currently, no data Available
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -€0.933 in its last earnings report, missing expectations of -€0.903. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Among the largest hedge funds holding Syndax Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Syndax Pharmaceuticals Inc’s shares valued at 33M.
---
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€31.37 (61.69% Upside)
€31.37 (61.69% Upside)
Blogger Sentiment
Bullish
DE:1T3 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.42%
12-Months-Change
Fundamentals
Return on Equity
-40.98%
Trailing 12-Months
Asset Growth
23.26%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
---
1T3 Company Deck
---
1T3 Earnings Call
Q4 2024
0:00 / 0:00
---
1T3 Stock 12 Months Forecast
Average Price Target
€31.37
▲(61.69% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
MacroGenics
―
Kura Oncology
―
Crispr Therapeutics AG
―
Rigel
―
Best Analysts Covering 1T3
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+15.56%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +15.56% per trade.
---